Literature DB >> 24424406

Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure.

Saverio Candido1, Venerando Rapisarda2, Andrea Marconi3, Grazia Malaponte1, Valentina Bevelacqua1, Pietro Gangemi4, Aurora Scalisi5, James A McCubrey6, Roberta Maestro7, Demetrios A Spandidos8, Concettina Fenga3, Massimo Libra1.   

Abstract

Sun-exposure is one of the risk factors associated with the development of a cutaneous neoplasm. In melanoma, the Ras-Raf-MEK-ERK (MAPK) signaling pathway is constitutively activated through multiple mechanisms, including B-Raf mutation. It has been hypothesized that B-Raf mutations in melanocytic lesions arise from DNA damage induced by ultraviolet (UV) radiation. However, it is still discussed if B-Raf mutations are associated with melanoma patients exposed to the sun. Therefore, in the present study, the known B-RafV600E mutation was analysed in melanoma samples from 30 indoor and 38 outdoor workers. B-RafV600E mutation was detected in 52 and 73% of outdoor workers and indoor workers, respectively. Of note, this mutation was identified in 12 of 14 (85%) melanoma of the trunk diagnosed in indoor workers and in 9 of 19 (47%) samples from outdoor workers (p=0.03). By analyzing melanomas of other body sites, no statistical difference in the frequency of B-RafV600E mutation was identified between the groups of workers. It appears that the mutation detected among indoor workers may be associated with a recreational or intermittent exposure to the sun, as usually the trunk is a sun-protected body site. Overall, these data indicate that the B-RafV600E mutation detected in melanoma is not associated with a chronic exposure to the sun. Mutations detected in other genes may also contribute to melanoma development in the subset of patients exposed to UV radiation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24424406      PMCID: PMC3926654          DOI: 10.3892/or.2014.2977

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


Introduction

Cutaneous melanoma (CM) is the most aggressive form of skin cancer. Its incidence has increased dramatically worldwide over the last 50 years (1). In Europe the highest incidence rates have been reported in Scandinavia (ca. 15 cases per 100,000 inhabitants and year) and the lowest in Mediterranean countries (ca. 5–7 cases per 100,000 inhabitants and year). In a worldwide comparison, the highest incidence rates have been reported in Australia (40–60 cases per 100,000 inhabitants and year) (2,3). Epidemiologic studies suggest that melanoma is determined by a complex model of pathways that are activated by many factors including genetic factors, phenotypic characteristics, number of melanocytic nevi, anatomic sites (lower limbs in females, posterior trunk in males), family history of melanoma, and the interplay with environmental factors, in particular for cutaneous melanoma, intense and intermittent exposure to ultraviolet (UV) radiation, represent the main risk factors (4). It is well-established and recognized that a genetic predisposition exists for the development of melanoma and nevi, especially the clinically atypical variants (5). CM results from uncontrolled melanocytic proliferation, melanin-producing cells located in the basal layer of the epidermis where they have a protective role against UV radiation for the skin by distributing melanin pigment from melanosomes to keratinocytes (5). Several studies of outdoor workers have shown an excess risk of melanoma and other skin cancers (6–10). The UVB component of the solar spectrum is the main source of risk for the development of a cutaneous neoplasm. Moreover, the cumulative lifetime dose of UVB radiation seems to be the most important factor for determining carcinogenic potential (3). Intense sun exposure leads both to DNA damage and to immunosuppression, which together are held to mediate carcinogenesis, while photo-adaptation is thought to reduce DNA damage (11). Solar radiation is a highly prevalent occupational exposure in farm, fishery and construction workers, letter carriers, gardeners, lumbermen, skiing instructors and mountain guides (12). Sun-exposed workers in the EU range from 29% in Germany to 51% in Greece and 39% in Italy (3). In melanoma, the Ras-Raf-MEK-ERK (MAPK) signaling pathway is constitutively activated through multiple mechanisms. Mutations of B-RAF have been proposed to contribute to melanoma development. V600E accounts for >60% of B-RAF mutations in melanoma and causes a substantial increase in B-Raf kinase activity (13). It has been suggested that B-RAF mutations in melanocytic lesions arise from DNA damage induced by UV radiation (14). However, it is still unclear if the B-RAFV600E mutations detected in melanoma patients results from their exposure to the sun. Therefore, the B-RAFV600E mutation was analysed in melanoma samples from patients with indoor and outdoor occupational activity.

Patients and methods

Patients

The subjects enrolled in this study included 68 consecutive patients diagnosed with cutaneous melanoma between October 1999 and June 2010. Tumor biopsy-specimens were isolated from 52 males and 16 females having at least 10 years of work history before the diagnosis of melanoma. All melanoma samples were collected by the Department of Bio-medical Sciences, University of Catania, Catania, Italy. The local scientific ethics committee approved all the procedures. The patients provided a written informed consent for the study. Medical files of each patient were analyzed for their occupational activity. Accordingly, patients were divided in two groups on the basis of their indoor or outdoor activity. Thirty-eight patient were outdoor workers, while 30 were indoor workers. In the group of outdoor workers there were: 11 farmers, 14 construction workers, 10 road paving workers, 2 beach attendant and 1 fisher man. In the group of indoor work there were: 11 office workers, 12 teachers, 1 Ph.D. student, 4 factory workers and 2 physicians. The duration of sun exposure for all outdoor workers was estimated as >6 h per day. Clinical patient characteristics are reported in Table I. DNA was isolated from each melanoma sample with the QIAgen Tissue kit (Qiagen, Valencia, CA, USA).
Table I

Clinical characteristics of melanoma patients.

Clinical featuresOutdoor (38)n (%)Indoor (30)n (%)P-value
Gender
 Male34 (89)18 (60)0.004
 Female4 (11)12 (40)
Age
 ≤5521 (55)16 (53)NS
 >5517 (45)14 (47)
Tumor type
 Primary melanoma25 (66)18 (60)NS
 Metastatic melanoma13 (34)12 (40)
Clark’s level
 III13 (34)13 (43)NS
 IV11 (29)17 (57)
 V1 (3)-
Breslow thickness
 ≤2.00 mm13 (34)10 (33)NS
 2.01–5.00 mm14 (37)10 (33)
 ≥5.00 mm11 (29)10 (33)
Tumor site
 Trunk19 (50)14 (47)NS
 Head and Necka12 (32)9 (30)
 Limbs7 (18)7 (23)

Including nose and scalp. NS, not significant.

B-RAFV600E mutation analysis

All DNA samples were screened in duplicate for B-RAFV600E mutation within exon 15 as previously described (15).

‘Cosmic Catalogue of Mutations in Cancer’ analysis

The website of the ‘Cosmic Catalogue of Mutations in Cancer’ (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) was explored imputing the following key words: ‘B-RAFV600E’, ‘melanoma’, ‘skin’, ‘intermittent sun exposure’ and ‘chronic sun exposure’.

Statistical analysis

Potential relationships between B-RAFV600E mutation and other patient characteristics were examined by the Chi-square test or Fisher’s exact test. A p-value <0.05 by a two tailed test was defined to be statistically significant.

Results

Clinical characteristics of melanoma patients are summarized in Table I. No differences in the main pathologic features between outdoor workers and indoor workers were observed except for the gender. The number of male outdoor workers was significantly higher compared to that of indoor workers (89 vs. 60%; p=0.004) (Table I). B-RAFV600E mutation was detected in 42 of 68 (61%) melanoma samples. Specifically, 21 out 42 (50%) mutations were observed in melanoma of the trunk, 29% in melanoma of the head and neck site and 21% of the limbs. B-RAFV600E mutation was detected in 20 of 38 (52%) outdoor workers and in 22 of 30 (73%) indoor workers. However, this difference was not statistically significant (Table II). In Table II, the distribution of B-RAFV600E mutation according to the tumor sites in both groups of outdoor and indoor workers is also shown. Notably, B-RAFV600E mutation was detected in 12 of 14 (85%) melanoma of the trunk diagnosed in indoor workers; while 47% of melanoma samples, occurred in outdoor workers, displayed this mutation in the same site (p=0.03). Similarly, higher number of mutations was observed in melanoma of the head and neck diagnosed among indoor workers when compared with those occurred among outdoor workers (78 vs. 42%). However, this difference was not statistically significant. B-RAFV600E mutation was detected in 43% of melanoma of the limbs among indoor workers; while 86% of mutations were detected in melanoma of the same sites among outdoor workers. No statistical difference was observed (Table II).
Table II

Distribution of B-RAFV600E mutation according to tumor sites in the groups of outdoor and indoor workers.

Tumor siteB-RAFV600E mutationOutdoorn (%)Indoorn (%)P-valuea
TrunkYes9 (47)12 (85)0.03
No10 (53)2 (15)
Total1914
Head and neckYes5 (42)7 (78)0.18
No7 (58)2 (22)
Total129
LimbsYes6 (86)3 (43)0.26
No1 (14)4 (57)
Total77
All sitesYes20 (52)22 (73)0.08
No18 (48)8 (27)
Total3830

Fisher’s exact test, Two-tailed.

To investigate whether B-RAFV600E mutations may occur differentially in melanoma patients chronically exposed to sun compared with those intermittently exposed to sun, further studies were performed by analyzing the ‘Cosmic Catalogue of Mutations in Cancer’. Higher B-RAFV600E mutation rate was detected in melanoma from patients with an intermittent exposure to sun when compared with those chronically exposed to sun (47 vs. 16%; p<0.0001) (Table III).
Table III

Distribution of B-RAFV600E mutation according to chronic exposure to sun and intermittent exposure to sun.a

B-RAFV600E mutationChronic exposure to sunn (%)Intermittent exposure to sunn (%)P-valueb
Yes9 (16)30 (47)<0.0001
No46 (84)34 (53)
Total5564

Cosmic Catalogue of Mutations in Cancer analysis;

Fisher’s exact test, Two-tailed.

Discussion

Risk factors associated with the increased incidence of melanoma are still debated. Genetic behavior and sun exposure represent the main players for cutaneous melanoma development (5,16). However, intermittent exposure to UV exposure has been demonstrated to have an increased risk of skin cancer (17). In recent years, a growing body of evidence supports a role of MAPK pathway in melanoma cell proliferation and survival (13,18). In this disease, the most frequent genetic alteration, which accounts for >60% of melanomas is the alteration of B-RAF, with a glutamic acid for valine substitution at codon 600 in exon 15 (Val600Glu; B-RAFV600E); this mutation introduces a conformational change in protein structure due to glutamic acid that acts as a phosphomimetic between the Thr598 and Ser601 phosphorylation sites, leading to constitutive activation of the protein with a large increase in the basal kinase activity; the resulting hyperactivity of the MAP kinase pathway promotes tumor development (13,18). To understand whether the B-rafV600E mutation is associated to chronic or intermittent sun exposure, in the present study we analyzed this mutation in melanoma from patients with and without occupational sun exposure assuming that indoor workers have an intermittent exposure to the sun. B-RAFV600E was mutated in 20 of 38 (52%) outdoor workers and in 22 of 30 (73%) indoor workers. Although, no statically significant difference was recorded, these data are in agreement with previous findings by Curtin et al (20) showing that B-RAFV600E mutation is not associated with a chronic sun exposure. Accordingly, most recent data indicated that occupational sun exposure did not increase risk of melanoma (9,19). Our study also analysed the B-RAFV600E mutation according to the tumor site between indoor and outdoor workers. This mutation was detected more frequently in melanoma of the trunk from indoor workers compared with outdoor workers. We can argue that the B-RAFV600E mutation detected among indoor workers may be associated with a recreational or intermittent exposure to the sun, as usually the trunk is a less frequently exposed body site. In fact, it was suggested that chronic exposure to the sun may induce photoadaption with increased melanisation and epidermal thickening (11). The higher frequency of B-RAFV600E mutation melanoma of the trunk in indoor workers is in line with previous data since this mutation was detected more frequently in melanoma of the trunk (20,21). Therefore, we can speculate that the melanocytes of melanoma patients, intermittently exposed to the sun, have an increased susceptibility to proliferate and acquire B-RAF mutations. Further analysis were performed by exploring the Cosmic Catalogue of Mutations in Cancer confirming that higher B-RAFV600E mutation rate is observed in melanoma from patients with an intermittent exposure to sun when compared with those chronically exposed to sun (47 vs. 16%; p<0.0001). In the study conducted by Whiteman et al (4) it has been shown that patients with chronic sun exposure may preferentially develop melanoma of the head and neck. Similarly, in our series melanoma of the head and neck was diagnosed in 12 outdoor workers and in 9 indoor workers, however, this difference did not reach significance due to the small number of the samples. Overall, these data support the notion that B-RAFV600E mutation detected in melanoma from outdoor workers is not associated with a chronic exposure to the sun. In contrast, indoor workers, that may be exposed to intermittent sunbathing, are more susceptible to developing a melanoma harboring B-RAFV600E mutation. These findings may have important therapeutic implications as melanoma patients with B-RAF mutations may benefits from B-RAF inhibition (18). Indication for a direct UV mutagenic effect in melanoma development remains still controversial as the nucleotide exchange detected in the B-RAF gene (T/A) is not classically linked to UV mutagenesis signature attributable to cytidine to thymidine (C>T) transitions. As proposed before, it is possible that B-RAF mutations could arise from error prone replication of UV-damaged DNA (14). However, a potential mechanism of melanoma development after UV-damage is described in Fig. 1. Mutations detected in other genes may also contribute to melanoma development in a subset of patients exposed to UV radiation (22).
Figure 1

Potential mechanism of melanoma development and progression after UV-damage. UVA, Ultraviolet A; UVB, ultraviolet B; CPDs, cyclobutane pyrimidine dimers; Fapy, formamidopyrimidines; 8-oxo-dG, 8-Oxo-2′-deoxyguanosine; G^T, guanine to thymidine transversion; B-RAF, v-raf murine sarcoma viral oncogene homolog B; CDKN2A, cyclin-dependent kinase inhibitor 2A; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; PTEN, phosphatase and tensin homolog; TP53, tumor protein p53; PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α; MITF, microphthalmia-associated transcription factor; APAF-1, apoptotic peptidase activating factor 1; AKT3, v-akt murine thymoma viral oncogene homolog 3.

  22 in total

Review 1.  The pathogenesis of melanoma induced by ultraviolet radiation.

Authors:  B A Gilchrest; M S Eller; A C Geller; M Yaar
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Cancer risk by occupation and socioeconomic group among men--a study by the Association of Swiss Cancer Registries.

Authors:  Christine Bouchardy; Georges Schüler; Christoph Minder; Philippe Hotz; Arnaud Bousquet; Fabio Levi; Thomas Fisch; Joachim Torhorst; Luc Raymond
Journal:  Scand J Work Environ Health       Date:  2002       Impact factor: 5.024

Review 3.  Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure.

Authors:  Sara Gandini; Francesco Sera; Maria Sofia Cattaruzza; Paolo Pasquini; Orietta Picconi; Peter Boyle; Carmelo Francesco Melchi
Journal:  Eur J Cancer       Date:  2005-01       Impact factor: 9.162

4.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.

Authors:  Martin Deichmann; Dieter Krahl; Marianne Thome; Kirsten Wüst; Judith Hassanzadeh; Burkhard Helmke
Journal:  Int J Oncol       Date:  2006-07       Impact factor: 5.650

6.  Analysis of BRAF mutation in primary and metastatic melanoma.

Authors:  Massimo Libra; Grazia Malaponte; Patrick M Navolanic; Pietro Gangemi; Valentina Bevelacqua; Lidia Proietti; Bibiana Bruni; Franca Stivala; Maria C Mazzarino; Salvatore Travali; James A McCubrey
Journal:  Cell Cycle       Date:  2005-10-13       Impact factor: 4.534

7.  Photoadaptation to ultraviolet (UV) radiation in vivo: photoproducts in epidermal cells following UVB therapy for psoriasis.

Authors:  V Bataille; V J Bykov; P Sasieni; S Harulow; J Cuzick; K Hemminki
Journal:  Br J Dermatol       Date:  2000-09       Impact factor: 9.302

Review 8.  Epidemiology of cutaneous melanoma in Germany and worldwide.

Authors:  C Garbe; A Blum
Journal:  Skin Pharmacol Appl Skin Physiol       Date:  2001 Sep-Oct

9.  Occupational sun exposure and risk of melanoma according to anatomical site.

Authors:  Kylie Vuong; Kevin McGeechan; Bruce K Armstrong; Anne E Cust
Journal:  Int J Cancer       Date:  2013-11-29       Impact factor: 7.396

10.  Cutaneous melanoma: hints from occupational risks by anatomic site in Swedish men.

Authors:  B Perez-Gomez; M Pollán; P Gustavsson; N Plato; N Aragonés; G López-Abente
Journal:  Occup Environ Med       Date:  2004-02       Impact factor: 4.402

View more
  19 in total

1.  Melanoma therapeutics: a literature review.

Authors:  Pavan Kumar Dhanyamraju; Trupti N Patel
Journal:  J Biomed Res       Date:  2022-02-28

Review 2.  MiR-21: an environmental driver of malignant melanoma?

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2015-06-27       Impact factor: 5.531

Review 3.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).

Authors:  George Mihai Nitulescu; Denisa Margina; Petras Juzenas; Qian Peng; Octavian Tudorel Olaru; Emmanouil Saloustros; Concettina Fenga; Demetrios Α Spandidos; Massimo Libra; Aristidis M Tsatsakis
Journal:  Int J Oncol       Date:  2015-12-24       Impact factor: 5.650

Review 4.  Occupational exposure to pesticides as a possible risk factor for the development of chronic diseases in humans (Review).

Authors:  Silvia Gangemi; Edoardo Miozzi; Michele Teodoro; Giusi Briguglio; Annamaria De Luca; Carmela Alibrando; Irene Polito; Massimo Libra
Journal:  Mol Med Rep       Date:  2016-10-10       Impact factor: 2.952

Review 5.  Occupational exposure to carcinogens: Benzene, pesticides and fibers (Review).

Authors:  Luca Falzone; Andrea Marconi; Carla Loreto; Sabrina Franco; Demetrios A Spandidos; Massimo Libra
Journal:  Mol Med Rep       Date:  2016-10-03       Impact factor: 2.952

6.  Phenotype characterization of human melanoma cells resistant to dabrafenib.

Authors:  Fabiola Gilda Cordaro; Anna Lisa De Presbiteris; Rosa Camerlingo; Nicola Mozzillo; Giuseppe Pirozzi; Ernesta Cavalcanti; Antonella Manca; Giuseppe Palmieri; Antonio Cossu; Gennaro Ciliberto; Paolo A Ascierto; Salvatore Travali; Eduardo J Patriarca; Emilia Caputo
Journal:  Oncol Rep       Date:  2017-09-18       Impact factor: 3.906

7.  Standardization of A375 human melanoma models on chicken embryo chorioallantoic membrane and Balb/c nude mice.

Authors:  Stefana Avram; Dorina-Elena Coricovac; Ioana Zinuca Pavel; Iulia Pinzaru; Roxana Ghiulai; Flavia Baderca; Codruta Soica; Danina Muntean; Daciana E Branisteanu; Demetrios A Spandidos; Aristides M Tsatsakis; Cristina Adriana Dehelean
Journal:  Oncol Rep       Date:  2017-05-22       Impact factor: 3.906

8.  NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.

Authors:  Claudio Guarneri; Valentina Bevelacqua; Jerry Polesel; Luca Falzone; Patrizia S Cannavò; Demetrios A Spandidos; Grazia Malaponte; Massimo Libra
Journal:  Oncol Rep       Date:  2017-01-10       Impact factor: 3.906

Review 9.  Emerging targeted therapies for melanoma treatment (review).

Authors:  Angela Russo; Bartolomea Ficili; Saverio Candido; Franca Maria Pezzino; Claudio Guarneri; Antonio Biondi; Salvatore Travali; James A McCubrey; Demetrios A Spandidos; Massimo Libra
Journal:  Int J Oncol       Date:  2014-06-03       Impact factor: 5.650

10.  MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma.

Authors:  Luca Falzone; Rossella Salemi; Salvatore Travali; Aurora Scalisi; James A McCubrey; Saverio Candido; Massimo Libra
Journal:  Aging (Albany NY)       Date:  2016-05       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.